Please use this identifier to cite or link to this item: https://doi.org/10.1186/2193-1801-3-245
DC FieldValue
dc.titleMiT translocation renal cell carcinomas: Two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]
dc.contributor.authorHora, M
dc.contributor.authorÜrge, T
dc.contributor.authorTrávní?ek, I
dc.contributor.authorFerda, J
dc.contributor.authorChudá?ek, Z
dc.contributor.authorVan??ek, T
dc.contributor.authorMichal, M
dc.contributor.authorPetersson, F
dc.contributor.authorKuroda, N
dc.contributor.authorHes, O
dc.date.accessioned2020-11-19T07:18:08Z
dc.date.available2020-11-19T07:18:08Z
dc.date.issued2014
dc.identifier.citationHora, M, Ürge, T, Trávní?ek, I, Ferda, J, Chudá?ek, Z, Van??ek, T, Michal, M, Petersson, F, Kuroda, N, Hes, O (2014). MiT translocation renal cell carcinomas: Two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)]. SpringerPlus 3 (1) : 1-Sep. ScholarBank@NUS Repository. https://doi.org/10.1186/2193-1801-3-245
dc.identifier.issn21931801
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/183715
dc.description.abstractIntroduction: MiT translocation renal cell carcinomas (TRCC) predominantly occur in younger patients with only 25% of patients being over 40 years. TRCC contains two main subgroups with translocations involving 6p21 or Xp11.2. Herein we present 10 cases. Materials: Eight cases were treated at main author's institution (identified among 1653 (0.48%) cases of kidney tumours in adults). Two cases were retrieved from the Pilsen (CZ) Tumour Registry. Results: Six cases were type Xp11.2 and four 6p21; 7 female, 3 male patients; Xp11.2 4:2, 6p21 3:1. The mean age 49 years (range: 21-80), 5 patients (50%) over 40 years. The mean age of the group with Xp11.2 TRCCs was 55 (median 51) and 6p21 41 (32) years. One female with a 6p21 tumour (24 years) underwent nephrectomy at 4 months of pregnancy. Stage (UICC, 7th ed. 2009) was 5xI, 3xIII, 2xIV. The mean size of tumour was 80 (40-165) mm. The mean follow-up was 33.2 (1-92) months. In patients with 6p21 tumours, one (25%) died after 3 months due to widely metastatic disease. In patients with Xp11.2 tumours, 3 (50%) succumbed due to metastatic disease (range 1-8 months). Three patients with Xp11.2 are alive at 7, 52 and 92 months of follow-up, were diagnosed at early stage (T1a). Conclusion: TRCCs were more common in females. Patient with 6p21 tumours were younger than those with Xp11.2. Both types have definitive malignant potential Type Xp11.2 seems to be a more aggressive neoplasm than 6p21. The case with metastatic 6p21 tumour is the 4th case described in the English literature. © 2014 Hora et al.; licensee Springer.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.typeArticle
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1186/2193-1801-3-245
dc.description.sourcetitleSpringerPlus
dc.description.volume3
dc.description.issue1
dc.description.page1-Sep
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_2193-1801-3-245.pdf1.77 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons